The paper entitled " Can fibrogenesis markers reflect early hepatic histopathology in chronic hepatitis C?" published in this issue of the AfroEgyptian journal of infectious and Endemic Diseases by Abou El-Azm et al., aimed at evaluating individual and combined non invasive indicators of fibrogenesis (MMP-2, T1MP1 and APRI score) to assess early hepatic histopathology, and developing cirrhosis in chronic HCV patients with and without symptoms. The authors enrolled 344 patients (Group I:129 asymptomatic chronic-HCV, Group II: 135 with symptoms and Group III: 80 patients with compensated HCV-related cirrhosis). For each patient, APRI-Score was evaluated. Quantitative immunoassay measured serum MMP-2 and TIMP-1. Guided liver biopsy for histopathology staging and grading was done. The results imply that combination of markers raised the sensitivity, specificity and correlations. It could reflect early hepatic histopathology, developing cirrhosis and potentially could replace liver biopsies in pre-treatment and follow up of chronic HCV.